Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 10.5 CAD -2.23%
Market Cap: 120.4m CAD

Intrinsic Value

The intrinsic value of one RX stock under the Base Case scenario is 12.16 CAD. Compared to the current market price of 10.5 CAD, Biosyent Inc is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RX Intrinsic Value
12.16 CAD
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Biosyent Inc

RX
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for RX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Biosyent Inc
XTSX:RX
CA
Pharmaceuticals
Market Cap
118.5m CAD
IPO
May 22, 1981
CA
Pharmaceuticals
Market Cap
118.5m CAD
IPO
May 22, 1981
Price
CA$false
EPS
CA$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RX?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Biosyent Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biosyent Inc

Current Assets 24.5m
Cash & Short-Term Investments 15.9m
Receivables 3m
Other Current Assets 5.5m
Non-Current Assets 16.9m
Long-Term Investments 10.1m
PP&E 1.2m
Intangibles 5m
Other Non-Current Assets 542.3k
Efficiency

Free Cash Flow Analysis
Biosyent Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Biosyent Inc

Revenue
35m CAD
Cost of Revenue
-7.2m CAD
Gross Profit
27.9m CAD
Operating Expenses
-18.8m CAD
Operating Income
9.1m CAD
Other Expenses
-1.8m CAD
Net Income
7.3m CAD
Fundamental Scores

RX Profitability Score
Profitability Due Diligence

Biosyent Inc's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Gross Profit
Positive Free Cash Flow
Exceptional ROIC
70/100
Profitability
Score

Biosyent Inc's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

RX Solvency Score
Solvency Due Diligence

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RX Price Targets Summary
Biosyent Inc

Wall Street analysts forecast RX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RX is 11.99 CAD with a low forecast of 11.87 CAD and a high forecast of 12.34 CAD.

Lowest
Price Target
11.87 CAD
13% Upside
Average
Price Target
11.99 CAD
14% Upside
Highest
Price Target
12.34 CAD
18% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for RX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one RX stock?

The intrinsic value of one RX stock under the Base Case scenario is 12.16 CAD.

Is RX stock undervalued or overvalued?

Compared to the current market price of 10.5 CAD, Biosyent Inc is Undervalued by 14%.

Back to Top